NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
In the year-ago quarter, Intellia had incurred a loss of $1.38 per share. The company's total revenues currently comprise only collaboration revenues. Intellia reported revenues of $9.1 million for the third quarter of 2024 compared with $12 million reported in the year-ago quarter. Revenues however beat the Zacks Consensus Estimate of $8 million. The year-over-year decrease in revenues was due to a reduction in revenues related to the AvenCell license and collaboration agreement. Shares of Intellia have plunged 47.6% year to date compared with the industry's decline of 2.4%. Image Source: Zacks Investment Research Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Intellia's collaboration revenues beat our model estimate of $8 million. Research and development expenses totaled $123.4 million, up 8.5% from the year-ago quarter's figure. The increase was due to the advancement of lead pipeline programs. General and administrative expenses increase
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire
- Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens BermanGlobeNewswire
- Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire
- ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNGlobeNewswire
- Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGNPR Newswire
REGN
Earnings
- 2/4/25 - Beat
REGN
Sec Filings
- 2/12/25 - Form SCHEDULE
- 2/7/25 - Form 13F-HR
- 2/5/25 - Form 10-K
- REGN's page on the SEC website